|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Eltrombopag (ELT) is a thrombopoietin receptor activator that has shown efficacy in chronic immune thrombocytopenia.
|
31205222 |
2020 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists.
|
31280643 |
2020 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Romiplostim (Nplate<sup>®</sup>), a thrombopoietin receptor agonist, is the first FDA-approved thrombopoiesis-stimulating protein for the treatment of low platelet (PLT) counts in adults with chronic immune thrombocytopenia.
|
31021662 |
2020 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Markers of endothelial cell activation and neutrophil extracellular traps are elevated in immune thrombocytopenia but are not enhanced by thrombopoietin receptor agonists.
|
31805421 |
2020 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thrombopoietin receptor agonist switch in children with persistent and chronic severe immune thrombocytopenia: A retrospective analysis in a large tertiary center.
|
30854783 |
2019 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia.
|
31156798 |
2019 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia.
|
29215956 |
2019 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
|
30880797 |
2019 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia.
|
31007886 |
2019 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations.
|
31818701 |
2019 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The thrombopoietin receptor (TPOR) agonist romiplostim (RP) is a therapeutic agent for immune thrombocytopenia and has potential to respond to such victims.
|
30926566 |
2019 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatment.
|
29293383 |
2019 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia.
|
31723222 |
2019 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Romiplostim is a thrombopoietin receptor agonist recommended as a second-line therapy for immune thrombocytopenia.
|
29298625 |
2019 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Romiplostim is a thrombopoietin receptor agonist approved for the treatment of immune thrombocytopenia purpura.
|
29357781 |
2019 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The thrombopoietin receptor agonist romiplostim is approved for second-line use in chronic immune thrombocytopenia (ITP), but its effects in patients with ITP for ≤1 year are not well characterized.
|
30793285 |
2019 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.
|
30191972 |
2018 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Autoantibodies to thrombopoietin and the thrombopoietin receptor in patients with immune thrombocytopenia.
|
29532903 |
2018 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists.
|
29848048 |
2018 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In absence of direct comparison, we conducted an indirect-comparison meta-analysis to evaluate the efficacy and safety of thrombopoietin-receptor agonists(TPO-RAs) in treatment of pediatric persistent or chronic immune thrombocytopenia(ITP).
|
29330464 |
2018 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenia: a meta-analysis.
|
29467954 |
2018 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thrombopoietin receptor agonists in patients with persistent or chronic immune thrombocytopenia.
|
29243329 |
2018 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists.
|
28275823 |
2017 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thrombopoietin-receptor-agonists (TPO-RAs) increase platelet production in Immune Thrombocytopenia (ITP) by stimulating Mpl.
|
27819522 |
2017 |
|
Autoimmune thrombocytopenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Eltrombopag (thrombopoietin-receptor agonist) and plasmapheresis as rescue therapy of acute post-renal transplant immune thrombocytopenia in a child with Schimke immuno-osseous dysplasia-case report.
|
27671102 |
2016 |